var data={"title":"Granisetron: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Granisetron: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6284?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=granisetron-drug-information\" class=\"drug drug_general\">see &quot;Granisetron: Drug information&quot;</a> and <a href=\"topic.htm?path=granisetron-patient-drug-information\" class=\"drug drug_patient\">see &quot;Granisetron: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177430\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Granisol [DSC];</li>\n      <li>Sancuso;</li>\n      <li>Sustol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177431\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Granisetron Hydrochloride Injection;</li>\n      <li>Granisetron Hydrochloride Injection SDZ;</li>\n      <li>Nat-Granisetron</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059048\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">5-HT<sub>3</sub> Receptor Antagonist</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiemetic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059043\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=granisetron-drug-information\" class=\"drug drug_general\">see &quot;Granisetron: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Granisol oral solution has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chemotherapy-induced nausea and vomiting (CINV), prevention: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: Children &ge;2 years and Adolescents: 10 mcg/kg administered within 30 minutes prior to chemotherapy; maximum dose: 1 mg/dose (ASCO [Basch], 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">POGO recommendations: Infants, Children, and Adolescents: 40 mcg/kg as a single daily dose prior to chemotherapy; POGO guidelines do not recommend a maximum dose; however, one study used a maximum dose of 3 mg regardless of bodyweight (Dupuis, 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: <i>Low to moderately emetogenic chemotherapy</i>: Infants, Children, and Adolescents: 40 mcg/kg/dose every 12 hours (Dupuis, 2013); usual adult dose: 1 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Transdermal: Adolescents &ge;18 years: Apply 1 patch at least 24 hours prior to chemotherapy; do not apply &ge;48 hours before chemotherapy. Remove patch a minimum of 24 hours after chemotherapy completion. Maximum duration: Patch may be worn up to 7 days, depending on chemotherapy regimen duration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postoperative nausea and vomiting, prevention:</b> Limited data available: Children and Adolescents: IV: 40 mcg/kg as a single dose; maximum dose: 0.6 mg/dose (Gan, 2014); ideal administration time in pediatric patients is not defined; in adults, administration is recommended at the end of surgery; in a granisetron pediatric PONV trial, doses were administered before the surgical incision (Cieslak, 1996; Gan, 2014). <b>Note:</b> QT prolongation has been observed at this dose in pediatric patients 2 to 16 years of age; monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chemotherapy-induced nausea and vomiting, prevention: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 2 mg once daily up to 1 hour before chemotherapy <b>or</b> 1 mg twice daily; the first 1 mg dose should be given up to 1 hour before chemotherapy. Administer only on the day(s) chemotherapy is given.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 10 mcg/kg 30 minutes prior to chemotherapy; only on the day(s) chemotherapy is given</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Transdermal patch: Apply 1 patch at least 24 hours prior to chemotherapy; may be applied up to 48 hours before chemotherapy. Remove patch a minimum of 24 hours after chemotherapy completion. Maximum duration: Patch may be worn up to 7 days, depending on chemotherapy regimen duration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prophylaxis of radiation therapy-associated emesis:</b> Oral: 2 mg once daily within 1 hour of radiation therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustments in renal impairment:</b> Children &ge;2 years, Adolescents, and Adults: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustments in hepatic impairment:</b> Children &ge;2 years, Adolescents, and Adults: Pharmacokinetic studies in patients with hepatic impairment showed that total clearance was approximately halved; however, standard doses were very well tolerated, and dose adjustments are not necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112378\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">Children &ge;2 years and Adolescents: No dosage adjustment necessary</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112379\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">Children &ge;2 years and Adolescents: Pharmacokinetic studies in patients with hepatic impairment showed that total clearance was approximately halved; however, standard doses were very well tolerated, and dose adjustments are not necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177433\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span><p>(For additional information <a href=\"topic.htm?path=granisetron-drug-information\" class=\"drug drug_general\">see &quot;Granisetron: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: Granisol oral solution has been discontinued in the US for more than 1 year.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of chemotherapy-associated nausea and vomiting:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 2 mg once daily up to 1 hour before chemotherapy or 1 mg twice daily; the first 1 mg dose should be given up to 1 hour before chemotherapy (with the second 1 mg dose 12 hours later). Administer only on the day(s) chemotherapy is given.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 10 mcg/kg within 30 minutes prior to chemotherapy; only on the day(s) chemotherapy is given.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ (extended-release injection): Moderately emetogenic chemotherapy or anthracycline/cyclophosphamide chemotherapy: 10 mg at least 30 minutes prior to chemotherapy on day 1 (in combination with IV dexamethasone on day 1 and [for anthracycline/cyclophosphamide chemotherapy] oral dexamethasone on days 2 to 4); do not administer more frequently than once every 7 days. May also be administered in combination with an NK<sub>1</sub> receptor antagonist antiemetic regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch: Prophylaxis of chemotherapy-related emesis: Apply 1 patch at least 24 hours prior to chemotherapy; may be applied up to 48 hours before chemotherapy. Remove patch a minimum of 24 hours after chemotherapy completion. Maximum duration: Patch may be worn up to 7 days, depending on chemotherapy regimen duration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Adult guideline recommendations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>American Society of Clinical Oncology (ASCO; Basch 2011): </i>High emetic risk:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 1 mg or 10 mcg/kg on the day(s) chemotherapy is administered (antiemetic regimen also includes dexamethasone and aprepitant or fosaprepitant)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 2 mg on the day(s) chemotherapy is administered (antiemetic regimen also includes dexamethasone and aprepitant or fosaprepitant)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Multinational Association of Supportive Care in Cancer (MASCC) and European Society of Medical Oncology (ESMO) (Roila 2016):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Highly emetic chemotherapy:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: 1 mg or 10 mcg/kg (antiemetic regimen includes dexamethasone and aprepitant/fosaprepitant) prior to chemotherapy on day 1</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral: 1 mg or 2 mg (antiemetic regimen includes dexamethasone and aprepitant/fosaprepitant) prior to chemotherapy on day 1</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderately emetic chemotherapy:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: 1 mg or 10 mcg/kg (antiemetic regimen includes dexamethasone [and aprepitant/fosaprepitant for AC chemotherapy regimen]) prior to chemotherapy on day 1</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral: 1 mg or 2 mg (antiemetic regimen includes dexamethasone [and aprepitant/fosaprepitant for AC chemotherapy regimen]) prior to chemotherapy on day 1</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Low emetic risk:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: 1 mg or 10 mcg/kg prior to chemotherapy on day 1</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral: 1 mg or 2 mg prior to chemotherapy on day 1</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis of radiation therapy-associated emesis:</b> Oral: 2 mg once daily within 1 hour of radiation therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of postoperative nausea and vomiting (off-label use): </b>IV: 0.35 to 3 mg (5 to 20 <b>mcg</b>/kg) administered at the end of surgery (Gan 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50991260\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV, Oral, Transdermal: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ (extended-release injection):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;60 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 59 mL/minute: 10 mg on day 1 of chemotherapy; do not administer more frequently than once every 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute: Avoid use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50988543\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Total clearance may be reduced by ~50% in patients with hepatic impairment. However, inter-subject variability limits interpretation of kinetic studies.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV, Oral, Transdermal: No dose adjustment necessary (standard doses are well tolerated).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ (extended-release injection): There is no dosage adjustment provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177407\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Patch, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sancuso: 3.1 mg/24 hr (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Prefilled Syringe, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sustol: 10 mg/0.4 mL (0.4 mL) [contains polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1 mg/mL (1 mL [DSC]); 1 mg/mL (1 mL); 4 mg/4 mL (4 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1 mg/mL (1 mL); 1 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Granisol: 2 mg/10 mL (30 mL [DSC]) [contains fd&amp;c yellow #6 (sunset yellow), sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177393\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46387648\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Granisol oral solution has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49037904\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Sustol: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM524796.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn//CovC0x0ey2BbNY46aAsKLqZAPV23SD0/arNwYzphnLw==&amp;TOPIC_ID=13341\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM524796.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059051\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Given at least 1 hour prior to chemotherapy/radiation; may be repeated 12 hours based on dose and indication</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: IV: Infuse over 30 seconds undiluted <b>or</b> dilute in small volume NS or D<sub>5</sub>W and administer over 5 minutes; infusions administered over 30 to 60 minutes have also been reported (Komada 1999; Miyajima1994; Wada 2001) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Transdermal (Sancuso): Apply patch to clean, dry, intact skin on upper outer arm. Do not use on red, irritated, or damaged skin. Remove patch from pouch immediately before application. Do not cut patch.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177425\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light. Do not freeze vials. Stable when mixed in NS or D5W for at least 24 hours at room temperature.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Store tablet or oral solution at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ (extended-release injection): Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. May be placed back in refrigerator after being kept at room temperature; may remain at room temperature for a maximum of 7 days. Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal patch: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Keep patch in original packaging until immediately prior to use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059050\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Prophylaxis of nausea and/or vomiting associated with initial and repeat courses of emetogenic chemotherapy including high-dose cisplatin (FDA approved in ages 2 to 16 years and adults); has also been used for prevention of postoperative nausea and vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral tablet: Prophylaxis of nausea and vomiting associated with emetogenic chemotherapy and radiation therapy (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal patch: Prophylaxis of nausea and vomiting associated with moderate to high emetogenic chemotherapy (FDA approved in ages &ge;18 years and adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2138081\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Granisetron may be confused with dolasetron, ondansetron, palonosetron</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177480\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypertension (oral and IV), prolonged Q-T interval on ECG (&gt;450 milliseconds, not associated with any arrhythmias)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation (IV), anxiety (oral and IV), central nervous system stimulation (IV), dizziness, drowsiness, headache (more common in oral and IV), insomnia (oral and IV)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, skin rash (IV)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, constipation (more common in oral and IV), decreased appetite, diarrhea (oral and IV), dysgeusia (IV), dyspepsia, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, leukopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT (&gt;2 x ULN), increased serum AST (&gt;2 x ULN)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Weakness (more common in oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Angina pectoris, application site reaction (transdermal: including allergic rash, burn, discoloration, erythema, erythematous rash, irritation, macular rash, pain, papular rash, pruritus, urticaria, vesicles), atrial fibrillation, atrioventricular block, bradycardia, cardiac arrhythmia, chest pain, ECG abnormality, extrapyramidal reaction, hypersensitivity reaction (includes anaphylaxis, dyspnea, hypotension, urticaria), hypotension, palpitations, serotonin syndrome, sick sinus syndrome, sinus bradycardia, syncope, ventricular ectopy (includes non-sustained tachycardia)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177414\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to granisetron or any component of the formulation or to other 5-HT3 receptor antagonists</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Concomitant use with apomorphine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177397\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; ECG effects: Selective 5-HT<sub>3</sub> antagonists, including granisetron, have been associated with a number of dose-dependent increases in ECG intervals (eg, PR, QRS duration, QT/QTc, JT), usually occurring 1 to 2 hours after IV administration. In general, these changes are not clinically relevant, however, when used in conjunction with other agents that prolong these intervals, arrhythmia may occur. When used with agents that prolong the QT interval (eg, Class I and III antiarrhythmics), clinically relevant QT interval prolongation may occur resulting in torsade de pointes. A number of trials have shown that 5-HT<sub>3</sub> antagonists produce QT interval prolongation to variable degrees.  Use with caution in patients at risk of QT prolongation and/or ventricular arrhythmia; patients with cardiac disease, electrolyte abnormalities, or who are receiving concomitant cardiotoxic chemotherapy are at higher risk. Reduction in heart rate may also occur with the 5-HT<sub>3</sub> antagonists. IV formulations of 5-HT<sub>3</sub> antagonists have more association with ECG interval changes, compared to oral formulations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal effects: Constipation may occur with all formulations, although a higher incidence is observed with tablets and the extended release subcutaneous injection. Hospitalization due to constipation or fecal impaction has been reported with the extended release subcutaneous injection. Progressive ileus and/or gastric distention may be masked by the extended release subcutaneous injection (assess risks/benefits in patients with recent abdominal surgery). Monitor for development of constipation and for decreased bowel activity, particularly in patients at risk for gastrointestinal obstruction. Granisetron does not stimulate gastric or intestinal peristalsis; do not use it in place of nasogastric suction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions (including anaphylaxis) have been reported with granisetron in patients who have experienced hypersensitivity to other 5-HT<sub>3</sub> antagonists (cross-reactivity has been reported). Due to the extended release properties of the subcutaneous formulation, granisetron exposure may continue for 5 to 7 days following administration; hypersensitivity reactions may occur up to 7 days or longer following administration and may have an extended course. Monitor for signs/symptoms of hypersensitivity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection site reactions: Injection site reactions are associated with the subcutaneous extended-release formulation. Injection site infections have been reported (median onset: 9 days); infections were managed with antibiotics and completely resolved. Bruising and/or hematomas occur in over one-third of patients (median onset: 2 days); may be delayed (~5 days or later following administration). Severe bruising has also been reported. Patients receiving anticoagulant or antiplatelet medications are at higher risk for severe bruising/hematoma at the injection site (consider risk/benefit in these patients). Injection site bleeding has also been observed, occasionally lasting &gt;5 days. Injection site pain/tenderness was commonly reported, usually lasting 5 to 7 days. Pain/tenderness interfered with activity or caused significant discomfort at rest (rare); some patients required pain medications. Injection site nodules occurred in less than one-fifth of patients, usually persisting for 15 to 21 days. Monitor for injection site reactions for at least 2 weeks after administration. If injection site reaction is not yet resolved prior to the next dose, rotate injection site with next administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome: Serotonin syndrome has been reported with 5-HT<sub>3</sub> receptor antagonists, predominantly when used in combination with other serotonergic agents (eg, SSRIs, SNRIs, MAOIs, mirtazapine, fentanyl, lithium, tramadol, and/or methylene blue). Some of the cases have been fatal. The majority of serotonin syndrome reports due to 5-HT<sub>3</sub> receptor antagonist have occurred in a postanesthesia setting or in an infusion center. Serotonin syndrome has also been reported following overdose of another 5-HT<sub>3</sub> receptor antagonist. Monitor patients for signs of serotonin syndrome, including mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis, dizziness, flushing, hyperthermia); neuromuscular changes (eg, tremor, rigidity, myoclonus, hyperreflexia, incoordination); gastrointestinal symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. If serotonin syndrome occurs, discontinue 5-HT<sub>3</sub> receptor antagonist treatment and begin supportive management.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Long QT syndrome: Use with caution in patients with congenital long QT syndrome or other risk factors for QT prolongation (eg, medications known to prolong QT interval, electrolyte abnormalities [hypokalemia or hypomagnesemia], and cumulative high-dose anthracycline therapy).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transdermal patch: Do not apply to red, irritated, or damaged skin. Application-site reactions have occurred with use; local reactions were generally mild and did not require discontinuation. If skin reaction is severe or generalized (allergic rash including erythematous, macular, or papular rash or pruritus), remove patch. Cover patch application site with clothing to protect from natural or artificial sunlight exposure while patch is applied and for 10 days following removal; granisetron may potentially be affected by natural or artificial sunlight. Do not apply heat (eg, heating pad) over or in area of the transdermal patch; avoid prolonged exposure to heat (may increase plasma concentrations).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chemotherapy-associated emesis: Antiemetics are most effective when used prophylactically (Roila 2016). If emesis occurs despite optimal antiemetic prophylaxis, re-evaluate emetic risk, disease, concurrent morbidities and medications to assure antiemetic regimen is optimized (Basch 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177470\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177402\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13341&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Apomorphine: Antiemetics (5HT3 Antagonists) may enhance the hypotensive effect of Apomorphine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: Granisetron may enhance the arrhythmogenic effect of Panobinostat. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: Antiemetics (5HT3 Antagonists) may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of Tapentadol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of TraMADol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177404\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177417\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. In an ex vivo placental perfusion study, granisetron was shown to cross the placenta in a concentration (dose) dependent manner (Julius 2014). Initial studies note the pharmacokinetics of the transdermal system may be different in pregnant women. A relationship between granisetron plasma concentrations and relief of symptoms of nausea and vomiting of pregnancy was also observed (Cartis 2016). Some dosage forms (injection) may contain benzyl alcohol.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177396\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Selective 5-HT<sub>3</sub>-receptor antagonist, blocking serotonin, both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177413\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: IV: 1 to 3 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Oral, IV: Generally up to 24 hours; SubQ (extended-release): Remains detectable in the plasma for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Tablets and oral solution are bioequivalent; Transdermal patch: ~66% over 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 2 to 4 L/kg; widely throughout body</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~65%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP1A1 and CYP3A4 N-demethylation, oxidation, and conjugation; some metabolites may have 5-HT<sub>3</sub> antagonist activity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Oral: 6 hours; IV: Mean range: 5 to 9 hours; SubQ (extended-release): ~24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Transdermal patch: Maximum systemic concentrations: ~48 hours after application (range: 24 to 168 hours); SubQ (extended-release): ~24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (11% to 12% as unchanged drug, 48% to 49% as metabolites); feces (34% to 38% as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51196157\" class=\"block phksp drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic function impairment: Total clearance is decreased by about 50% in patients with hepatic impairment (due to neoplastic disease) compared to patients with normal hepatic function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Geriatric: Mean values were lower for Cl and longer for half-life.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gender: Men had a higher C<sub>max</sub>, but there was no difference in AUC.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11376409\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Commercial oral solution is available (0.2 mg/mL)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A 0.2 mg/mL oral suspension may be made with tablets. Crush twelve 1 mg tablets in a mortar and reduce to a fine powder. Add 30 mL distilled water, mix well, and transfer to a bottle. Rinse the mortar with 10 mL cherry syrup and add to bottle. Add sufficient quantity of cherry syrup to make a final volume of 60 mL. Label &ldquo;shake well&rdquo;. Stable 14 days at room temperature or refrigerated (Quercia 1997).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A 50 mcg/mL oral suspension may be made with tablets and one of three different vehicles (Ora-Sweet&reg;, Ora-Plus&reg;, or a mixture of methylcellulose 1% and Simple Syrup, N.F.). Crush one 1 mg tablet in a mortar and reduce to a fine powder. Add 20 mL of the chosen vehicle and mix to a uniform paste; transfer to a calibrated bottle. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable for 91 days refrigerated (Nahata 1998).</p>\n    <div class=\"reference\">Nahata MC, Morosco RS, and Hipple TF, &quot;Stability of Granisetron Hydrochloride in Two Oral Suspensions,&quot; <i>Am J Health Syst Pharm</i>, 1998, 55(23):2511-3.<span class=\"pubmed-id\">9853637</span></div>\r\n\n    <div class=\"reference\">Quercia RA, Zhang J, Fan C, et al, &quot;Stability of Granisetron Hydrochloride in an Extemporaneously Prepared Oral Liquid,&quot; <i>Am J Health Syst Pharm</i>, 1997, 54(12):1404-6.<span class=\"pubmed-id\">9194985</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177416\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch</b> (Sancuso Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.1 mg/24 hrs (1): $640.26</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Prefilled Syringe</b> (Sustol Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/0.4 mL (0.4 mL): $639.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Granisetron HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/mL (1 mL): $12.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1 mL): $24.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/4 mL (4 mL): $200.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Granisetron HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (20): $1,180.18</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177418\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anavo (BD);</li>\n      <li>Degrani (ID);</li>\n      <li>Emegran (ID);</li>\n      <li>Frezitron (PH);</li>\n      <li>Gomsetron (VN);</li>\n      <li>Gramet (ID);</li>\n      <li>Granicip (IN);</li>\n      <li>Graniset (BD);</li>\n      <li>Granison (BD);</li>\n      <li>Granitron (QA);</li>\n      <li>Granon (ID);</li>\n      <li>Granored (HR);</li>\n      <li>Grant (ID);</li>\n      <li>Grantron (TW);</li>\n      <li>Gratril (KR);</li>\n      <li>Gratril OD (KR);</li>\n      <li>Helminar (PE);</li>\n      <li>Kevatril (DE);</li>\n      <li>Kyotil (TW);</li>\n      <li>Kytril (AE, AR, AT, AU, BE, BF, BG, BH, BJ, BR, CH, CI, CL, CO, CY, CZ, DK, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HN, HR, HU, IE, IL, IQ, IR, IT, JO, JP, KE, KR, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, OM, PE, PH, PK, PL, PT, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SY, TH, TN, TR, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);</li>\n      <li>Kytron (MY);</li>\n      <li>Nisetron (CO);</li>\n      <li>Opigran (ID);</li>\n      <li>Sancuso Patch (GB, HK, IE, KR, LT, MT, PH, QA, SK);</li>\n      <li>Setron (IL, TW);</li>\n      <li>Sulingqiong (CN);</li>\n      <li>Trilemes (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Vomitron (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/granisetron-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/granisetron-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2011;29(31):4189-4198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/granisetron-pediatric-drug-information/abstract-text/21947834 /pubmed\" target=\"_blank\" id=\"21947834 \">21947834 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/granisetron-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cieslak GD, Watcha MF, Phillips MB, Pennant JH. The dose-response relation and cost-effectiveness of granisetron for the prophylaxis of pediatric postoperative emesis. <i>Anesthesiology</i>. 1996;85(5):1076-1085.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/granisetron-pediatric-drug-information/abstract-text/8916825 /pubmed\" target=\"_blank\" id=\"8916825 \">8916825 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/granisetron-pediatric-drug-information/abstract-text/23512831 /pubmed\" target=\"_blank\" id=\"23512831 \">23512831 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gan TJ, Diemunsch P, Habib AS, et al. Consensus guidelines for the management of postoperative nausea and vomiting. <i>Anesth Analg</i>. 2014;118(1):85-113.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/granisetron-pediatric-drug-information/abstract-text/24356162 /pubmed\" target=\"_blank\" id=\"24356162 \">24356162 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Granisetron hydrochloride injection [prescribing information]. Sellersville, PA: Teva Pharmaceuticals USA; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Granisetron hydrochloride tablets [prescribing information]. Sellersville, PA: Teva Pharmaceuticals USA; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hahlen K, Quintana E, Pinkerton CR, et al, &ldquo;A Randomized Comparison of Intravenously Administered Granisetron Versus Chlorpromazine Plus Dexamethasone in the Prevention of Ifosfamide-Induced Emesis in Children,&rdquo; <i>J Pediatr</i>, 1995, 126(2):309-13. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/granisetron-pediatric-drug-information/abstract-text/7844684/pubmed\" target=\"_blank\" id=\"7844684\">7844684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Komada Y, Matsuyama T, Takao A, et al. A randomised dose-comparison trial of granisetron in preventing emesis in children with leukaemia receiving emetogenic chemotherapy. <i>Eur J Cancer</i>. 1999;35(7):1095-1101.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/granisetron-pediatric-drug-information/abstract-text/10533454 /pubmed\" target=\"_blank\" id=\"10533454 \">10533454 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lemerle J, Amaral D, Southall DP, et al, &ldquo;Efficacy and Safety of Granisetron in the Prevention of Chemotherapy-Induced Emesis in Paediatric Patients,&rdquo; <i>Eur J Cancer</i>, 1991, 27(9):1081-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/granisetron-pediatric-drug-information/abstract-text/1659848/pubmed\" target=\"_blank\" id=\"1659848\">1659848</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miyajima Y, Numata S, Katayama I, Horibe K. Prevention of chemotherapy-induced emesis with granisetron in children with malignant diseases. <i>Am J Pediatr Hematol Oncol</i>. 1994;16(3):236-241.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/granisetron-pediatric-drug-information/abstract-text/8037342 /pubmed\" target=\"_blank\" id=\"8037342 \">8037342 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wada I, Takeda T, Sato M, et al. Pharmacokinetics of granisetron in adults and children with malignant diseases. <i>Biol Pharm Bull</i>. 2001;24(4):432-435. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/granisetron-pediatric-drug-information/abstract-text/11305610 /pubmed\" target=\"_blank\" id=\"11305610 \">11305610 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13341 Version 167.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F177430\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F177431\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1059048\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F1059043\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51112378\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51112379\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F177433\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50991260\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50988543\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F177407\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F177393\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F46387648\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F49037904\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1059051\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F177425\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1059050\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2138081\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F177480\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F177414\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F177397\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F177470\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F177402\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F177404\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F177417\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F177396\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F177413\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Considerations\" href=\"#F51196157\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F11376409\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F177416\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F177418\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13341|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=granisetron-drug-information\" class=\"drug drug_general\">Granisetron: Drug information</a></li><li><a href=\"topic.htm?path=granisetron-patient-drug-information\" class=\"drug drug_patient\">Granisetron: Patient drug information</a></li></ul></div></div>","javascript":null}